At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 66 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis
In Brief
A Phase 4 clinical trial evaluating Ranibizumab for Age-Related Macular Degeneration. Completed, enrolled 66 participants across 1 site.
Detailed Summary
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedNov 2011
Primary CompletionDec 2011
Study CompletionJan 2013
TodayJul 2026
First PostedNov 3, 2011
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2011
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.7 years ago
Interventions
Ranibizumabdrug
Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.